Recent Articles from GlobeNewswire

World’s largest independent hotel brand strengthens its portfolio in Q3 2026

Premium Formulation Delivers Multi-Benefit Support for Cognitive Function, Muscle, Skin and Bone Health in Perimenopausal and Menopausal Women

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) --

ROCKY HILL, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- ALIRT Insurance Research has released a new report examining U.S. life insurers’ exposure to "alternative" investments reported through Schedule BA of statutory financial statements. The analysis reviews alternative investment growth trends, portfolio composition, and investment performance, as well as regulatory changes affecting alternative asset holdings across the life insurance sector.

BOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a late-breaking oral presentation on micvotabart pelidotin (MICVO) monotherapy in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, to take place in Barcelona, Spain, November 18 - November 20, 2026.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) --

PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) --

WUHU, China, Oct. 27, 2026 (GLOBE NEWSWIRE) -- As competition in the global automotive market continues to evolve, automakers are exploring ways to fuse technological innovation and product development with local market needs. Under the theme “Future Travel Starts Now,” the 2026 SOUEAST Global Technology Experience Day recently concluded, showcasing the brand’s hybrid technology, product strength, global presence, and progress in implementing its “Travel+” strategy. Through real-world mobility scenarios, SOUEAST demonstrated how innovation can translate into tangible driving experiences, catering to diverse needs from daily commutes to leisure travel.

NewBeauty, Shape and AskMen Recognize the Surgeon-Developed Brand’s Exfoliating Pads and Serums

MAYFIELD VILLAGE, OHIO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- As previously announced, The Progressive Corporation (NYSE: PGR) will host an Investor Relations conference call on Tuesday, November 3, 2026, beginning at 9:30 a.m. eastern time. This quarterly call, which will consist of both a conference call and audio-only webcast, is scheduled to last 60 minutes and will consist of a question-and-answer session with Tricia Griffith, our CEO, and Andrew Quigg, our CFO. Call-in participants will be able to ask questions via phone, however, webcast participants will not be able to submit questions online.

Implementation expected November 5, 2026; new Critical Metals Corp shares expected to begin trading on Nasdaq November 6, 2026

VISTA, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Flux Power Holdings, Inc. (NASDAQ: FLUX), a leading developer of advanced lithium-ion energy storage solutions and fleet intelligence technology, will report its 2027 fiscal first quarter results on Tuesday, November 3, 2026, after market close. Krishna Vanka, Chief Executive Officer, and Kevin Royal, Chief Financial Officer, will host a conference call at 4:30 p.m. ET to discuss the Company’s financial results, followed by a question-and-answer session.

More than 650 innovators from 14 countries submitted over 230 AI-focused projects designed to improve customer outcomes and connect innovation across Rocket Software’s portfolio

ELMNT IR also became the first account on the West Coast, marking a geographic expansion which aligns with the Company’s Full Market Release strategy. 

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- via AINewsWire — Nightfood Holdings Inc. (OTCQB: NGTFD) today announces its placement in an editorial published by AINewsWire ("AINW"), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

Approval follows early adoption across 75 dealerships, expanding access to AI-powered technology that helps service departments capture missed appointment opportunities

LIBERTY LAKE, Wash., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Itron, Inc. (NASDAQ: ITRI), which is innovating new ways for utilities and cities to manage energy and water, announced today financial results for its third quarter ended September 30, 2026. Key results for the quarter include (compared with the third quarter of 2025):

Expanding the AI ecosystem with Mistral AI, VAST Data, Neo4j and Cartesia brings greater choice across enterprise knowledge, models, voice, and infrastructure

LAS VEGAS, Oct. 27, 2026 (GLOBE NEWSWIRE) -- TON Strategy Company (“TON Strategy” or the “Company”) (Nasdaq: TONX), a digital asset treasury company dedicated to supporting The Open Network ("TON") ecosystem, will hold a conference call on Tuesday, November 10, 2026 at 9:00 a.m. Eastern time to discuss its financial results for the third quarter ended September 30, 2026. Financial results will be issued in a press release prior to the call.

Echo Tabletop Priced at $11,950 and Echo Full Body at $59,950; First Production Run of 250 Units Available for 2027 Delivery; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp.

Autopilot Negotiator runs parallel rate negotiations with carriers within customer-set price limits, allowing operators to book negotiated freight with a single click; Zayren Analytics, available in the Enterprise plan, lets logistics teams query their TMS data in plain language

Company marks two decades of growth, approaching 650 MW operating across nearly 175 sites nationwide

Milestone advances Clearmind’s clinical program as the company continues to develop CMND‑100 as a potential novel therapeutic candidate for alcohol use disorder

Transaction provides for the sale of Nexera’s wholly owned subsidiary, KeepZone AI, for $1 million in acquiror securities at closing and up to $5 million in additional cash earn-out consideration based on KeepZone AI’s net profit over the following 24 months

All 120 planned participants randomized across five clinical sites in the United States

Program Builds on Recent Retail Expansion and Creates Opportunities for Increased Holiday Sales

COLUMBUS, Ohio, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Bread Financial Holdings, Inc. (NYSE: BFH) (“Bread Financial” or the “Company”) announced today the launch of an underwritten public offering of depositary shares (the “Depositary Shares”), each representing a 1/40th interest in a share of its Fixed Rate Reset Non-Cumulative Perpetual Preferred Stock, Series C, par value $0.01 per share (the “Series C Preferred Stock”), with a liquidation preference of $25 per Depositary Share (equivalent to $1,000 per share of Series C Preferred Stock).

Hod HaSharon, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Allot Ltd. (NASDAQ: ALLT, TASE: ALLT), a leading global provider of innovative Security-as-a-Service (SECaaS) and network intelligence solutions for communications service providers and enterprises, announced today that it will host a conference call to discuss its third quarter 2026 results on Thursday, November 12, 2026 at 8:30AM ET (1:30PM UK, 3:30PM Israel).

NEEDHAM, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will participate in analyst-led fireside discussions and one-on-one meetings at upcoming investor conferences in November 2026.

MENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company will participate in two upcoming investor conferences.

New solution moves inactive data to an economical, protected tier to delay storage expansion, supported by a partner ecosystem including Komprise, Starfish Storage and rclone.

Latest CloudCasa update adds a preview of backups using Changed Block Tracking

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 27, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) ("CDT" or the "Company"), today announced that it has entered into an evaluation agreement with Manoira Corporation ("Manoira"), a specialty animal health company, to assess the potential of CDT's clinical-stage assets AZD1656, including certain proprietary cocrystal derivatives, and AZD5904 to enhance Manoira's forthcoming animal health products.

NeuroOne’s FDA 510(k)-Cleared OneRF Trigeminal Nerve Ablation System Offers Hope for Patients Suffering from Trigeminal Neuralgia

Third Quarter 2026 Financial Highlights

Award-winning certification exam prep platform introduces ‘Tutor’ to help adult learners retrieve the knowledge they already know, connect it to new concepts, and retain what they learn

400,000-square-foot site will support growing customer demand in the infrastructure vertical, including data centers and power utilities

NEW ORLEANS, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Humanitas Global Health, a mission-driven initiative applying explainable, traceable artificial intelligence and breakthrough science to reduce preventable suffering and expand access to better care worldwide, today announced its launch and an agreement licensing DeepDrug technologies from Louisiana State University for commercialization. Humanitas translates promising discoveries into practical tools that accelerate drug development, improve medication safety, and support more precise clinical decisions.

Second consecutive year on the ranking, reflecting sustained growth, financial strength, and stock performance

Vancouver, British Columbia, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Terra Balcanica Resources Corp. (“Terra” or the “Company”) (CSE:TERA; FRA:UB10; OTCQB:TEBAF) is pleased to announce that Terra North Resources Corp. (“Terra North”), in which Terra owns 35.1% equity, has received the final dataset from the previously announced airborne survey conducted over its flagship Charlot-Neely Lake claims located ca. 20 km north of Uranium City, Saskatchewan (see the Company's news release dated September 4th, 2026). Terra North holds an option to acquire 100% interest in the Project from Fulcrum Metals Canada Ltd. subject to satisfying certain earn-in requirements (see the Company's news release dated July 3rd, 2024).

Naples, Italy and Hamilton, Bermuda, Oct. 27, 2026 (GLOBE NEWSWIRE) -- The RoyaLand Company Ltd. (the “Company” or “RoyaLand”) (OTCQB: RLNDF), a Bermuda holding company focused on creating immersive, fantasy-based royalty-themed games and growing its Italian professional football club Savoia 1908 FC, today revealed more about Regalia Cards, a free to play mobile card game in which the noble houses of a royal court compete for honor across the card table. Built for iOS and Android, the game is targeting a Q4 2026 launch.

Thousands of amazing holiday finds for $5 and below, from viral squishies and Christmas tree trimmings to toys, stocking stuffers and more

SINGAPORE, Oct. 27, 2026 (GLOBE NEWSWIRE) -- HomesToLife Ltd (Nasdaq: HTLM) (“HomesToLife” or the “Company”), a Cayman Islands exempted company headquartered in Singapore with sales across Asia-Pacific, Europe and North America, today announced the results of an extraordinary general meeting (the “EGM”) held on October 27, 2026 at 10:00 A.M., Singapore Time (10 P.M. Eastern Time on Oct 26, 2026). The successful completion of the EGM represents a key milestone in the Company’s proposed secondary listing by way of an introduction of its ordinary shares on the Mainboard of the SGX-ST (the “Proposed Secondary Listing”).

NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Bexorg, Inc., a precision neurology company, built on an integrated AI and whole-human brain platform, today announced the appointment of Mikael Dolsten, M.D., Ph.D., as Chairman of its Board of Directors. Dr. Dolsten brings more than three decades of global leadership across research and development, including strategy and portfolio management, with experience spanning small-molecule medicines, biotherapeutics, gene therapies and vaccines. He succeeds Zvonimir Vrselja, M.D., Ph.D., Co-Founder and Chief Executive Officer, who has served as Chairman since the company’s founding and will continue as CEO and a member of the Board. The company also announced that Jon Faiz Kayyem, Ph.D., is retiring from the Board after serving as an independent director.

TEL AVIV, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that it has completed the acquisition of assets from BioXcel Therapeutics, Inc., including worldwide rights to BXCL501. BXCL501 is an investigational dexmedetomidine sublingual film under FDA review for at-home use in the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. If approved, BXCL501 would be the first FDA-approved treatment patients could use at home for this condition. The acquisition expands Teva’s innovative neuroscience pipeline with a late-stage asset with the potential to address a significant unmet patient need.

Portage, Michigan, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Jefferies Global Healthcare Conference on Tuesday, November 17, 2026, at the Waldorf Hilton and ME Hotel in London.

New leaders round out TrueCommerce’s executive bench as the company advances intelligent, connected supply chain operations

Co-founders to step down from executive roles and continue to serve on the Board of Directors

Across hundreds of studies and focus groups with 7,000+ legal professionals, lawyers describe the same friction: disconnected AI experiences, lost context, lack of verification, and time wasted formatting work 

WASHINGTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- The latest CapEx Finance Index (CFI), released today by the Equipment Leasing & Finance Association (ELFA), showed that equipment demand remained strong in September. New business volume was essentially unchanged from August, making September the third-strongest month in the survey's history, and the full-year forecast held steady at an all-time high. Financial conditions remained healthy, with the delinquency rate falling to its lowest level since April 2023. Additional Fed rate hikes and elevated economic uncertainty remain risks, but strong demand and healthy credit quality leave the industry well positioned heading into the final quarter of the year.

2026 Outlook Raised on Record Profitability; Millar Acquisition Advances Diversification

The agreement supports EyeLief® combination drug-device product development in anticipation of a future clinical program, with polymer supply also supporting OcuLief® and non-ocular applications

BERLIN, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Global energy technology leader Schneider Electric, industrial software leader AVEVA, full-stack AI cloud platform Nscale, and data center developer and operator Start Campus, today announced the successful pilot of an end-to-end digital twin developed using the NVIDIA Omniverse DSX Blueprint, part of NVIDIA DSX Sim.

With the Flatiron Institute and leading European research institutions, Pasqal used its 256-qubit processor to observe an unexpected slowdown in a 2D quantum magnet, in a regime that current theory and classical simulations cannot yet reliably predict.

  

WILMINGTON, Del., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Global Indemnity Group, LLC (NASDAQ:GBLI) (“GBLI”) announced today that it will release its third quarter 2026 earnings results before market open on Wednesday, November 4, 2026.

Following its recent offtake agreement and increased commercial demand, Emvolon raises Series A and non-dilutive federal and state grants to launch first commercial system and adds industry growth veteran to its board to accelerate project pipeline

Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy Platforms

Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE: OGN)

Single-dose CLD-401 induced tumor regression and complete response in 80% of mice in EMT6 breast tumor model

Approval under the EU Clinical Trials Regulation builds on CAMP4’s recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company’s global Phase 1/2 trial of CMP-002

VANCOUVER, Wash. and NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the following upcoming investor conferences:

WILMINGTON, Del., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today announced that the Company’s management will be participating in the following investor conferences during the month of November and December 2026.

Nes-Ziona, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced receipt of a delisting notification dated October 26, 2026 (the “Delisting Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market Inc. (“Nasdaq”), stating that the closing bid price of the Company’s ordinary shares during the 30 consecutive business days prior to October 22, 2026 did not meet the $1.00 minimum bid price requirement in accordance with Nasdaq Listing Rule 5550(a)(2).  Because the Company effected a reverse share split within the preceding 12 months, the Company is not entitled to a 180-day period to regain compliance with the minimum bid price requirement.

BRIDGEWATER N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 a.m. ET on Tuesday, November 10, 2026, to review third quarter 2026 financial results.

New experience introduces Lu, an AI-powered insurance guide that allows consumers to compare coverage through conversation and get real-time quotes they can act on

Quarterly Highlights:

Planning underway for registrational trial of WVE-006 (RNA editing) in AATD, with an interim analysis for potential accelerated approval based on AATD biomarkers

Private equity operations expert brings more than 20 years of experience helping investors and portfolio companies improve EBITDA, optimize operations and accelerate enterprise value creation

Shelton, CT, Oct. 27, 2026 (GLOBE NEWSWIRE) --

Jena, Germany, Oct. 27, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its events calendar for November.

Company’s Executive Chairman and CEO to Speak on Cancer Therapeutics Spotlight Panel at BioFuture in NYC and Deliver Keynote Address at Global Biotechnology Summit in Abu Dhabi

HOLLISTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2026, before the market opens on November 10, 2026, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. 

Latest DSP integration expands buyer access to OptimizeRx point of care inventory through existing programmatic workflows

SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva or the Company), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that it will discontinue further development of AlloNK® (AB-101), its non-genetically modified, allogeneic NK cell therapy candidate being evaluated in combination with rituximab in rheumatoid arthritis (RA) and other B-cell-driven autoimmune diseases. The decision follows the Company’s review of the overall risk-benefit in the context of updated clinical data, including longer-term follow-up, and recent Grade 5 safety events. The Company also announced that it is implementing a reduction in workforce and evaluating strategic alternatives to maximize stockholder value that may include a merger, business combination, sale or licensing of assets, or dissolution and liquidation.